2. Others
  3. Others
  4. A2-Iso5-2DC18

A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma..

For research use only. We do not sell to patients.

A2-Iso5-2DC18 Chemical Structure

A2-Iso5-2DC18 Chemical Structure

CAS No. : 2412492-07-8

Size Price Stock Quantity
1 mg USD 170 In-stock
5 mg USD 350 In-stock
10 mg USD 560 In-stock
25 mg USD 1100 In-stock
50 mg USD 1760 In-stock
100 mg USD 2820 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

A2-Iso5-2DC18 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma.[1].

In Vivo

A2-Iso5-2DC18, loaded with mLuc or Cre-recombinase mRNA LNPs (mCre), (0.1 mg/kg and 0.5 mg/kg; s.c.; once a week, for 2 weeks) transfects central antigen presenting cells (APCs) in A14/Cre mRNA mouse model[1].
A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccine, (15 μg mOVA per mouse; s.c.; twice dose, once every 5 d) induces a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response, in parallel with robust IFN-ɤ secretion in B16F10 mouse melanoma model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A14/Cre mRNA mouse model (female B6 mice)[1]
Dosage: Loaded with Cre-recombinase mRNA LNPs (mCre); 0.1 mg/kg and 0.5 mg/kg
Administration: Subcutaneous injection; 3 weeks
Result: Induced protein expression in the local injection site and the draining lymph nodes and transfected central antigen presenting cells (APCs) including macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) in mice.
Animal Model: Ovalbumin (OVA)-expressing B16F10 mouse melanoma model[1]
Dosage: Loaded with OVA mRNA (mOVA) vaccine; 15 μg mOVA per mouse
Administration: Subcutaneous injection; once per week for the first two weeks; 3 weeks continuous observation
Result: Significantly decreased tumor volume of B16-OVA melanoma and improved overall survival in mice.
Increased the number of systemic and tumor-infiltrating antigen-specific T cells dramatically (20–30-fold).
Molecular Weight

726.21

Formula

C47H87N3O2
CAS No.
Appearance

Liquid

Color

Light yellow to yellow

SMILES

CCCCCCCC/C=C\CCCCCCCC1(C=NC(C(OCC)=O)N1CCCN2CCCC2)CCCCCCC/C=C\CCCCCCCC
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (137.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.3770 mL 6.8851 mL 13.7701 mL
5 mM 0.2754 mL 1.3770 mL 2.7540 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (3.44 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.3770 mL 6.8851 mL 13.7701 mL 34.4253 mL
5 mM 0.2754 mL 1.3770 mL 2.7540 mL 6.8851 mL
10 mM 0.1377 mL 0.6885 mL 1.3770 mL 3.4425 mL
15 mM 0.0918 mL 0.4590 mL 0.9180 mL 2.2950 mL
20 mM 0.0689 mL 0.3443 mL 0.6885 mL 1.7213 mL
25 mM 0.0551 mL 0.2754 mL 0.5508 mL 1.3770 mL
30 mM 0.0459 mL 0.2295 mL 0.4590 mL 1.1475 mL
40 mM 0.0344 mL 0.1721 mL 0.3443 mL 0.8606 mL
50 mM 0.0275 mL 0.1377 mL 0.2754 mL 0.6885 mL
60 mM 0.0230 mL 0.1148 mL 0.2295 mL 0.5738 mL
80 mM 0.0172 mL 0.0861 mL 0.1721 mL 0.4303 mL
100 mM 0.0138 mL 0.0689 mL 0.1377 mL 0.3443 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

A2-Iso5-2DC18 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

A2-Iso5-2DC182412492-07-8OthersmRNA delivery vehicleNKnatural killer cellsDCdendritic cellsMΦmacrophages/monocytesAPCantigen-presenting cellsB16F10 melanomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
A2-Iso5-2DC18
Cat. No.:
HY-151509
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.